Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

VO2max and Substrate Crossover Point (VO2MAX-CROSS)

28 août 2026 mis à jour par: Celil Kaçoğlu

Higher VO2max Delays Substrate Switching and Shifts the Crossover Point to Greater Oxygen Uptake During Incremental Exerciseebys

This study aims to investigate the relationship between maximal oxygen uptake (VO2max) and the substrate crossover point during incremental exercise. A total of 20 physical education students are recruited to complete a maximal incremental treadmill test using the standard Bruce protocol. Indirect calorimetry is utilized to assess oxygen uptake (VO2), carbon dioxide production (VCO2), and energy substrate utilization patterns. The substrate crossover point is operationally defined at a respiratory exchange ratio (RER) threshold of 0.85, indicating the metabolic transition toward predominant carbohydrate oxidation. The primary objective is to evaluate how variations in aerobic capacity influence the timing, oxygen uptake, and heart rate (HR) responses at this metabolic transition threshold.

Aperçu de l'étude

Description détaillée

This study evaluates the relationship between maximal oxygen uptake (VO2max) and the substrate crossover point during incremental treadmill exercise in young, physically active individuals. Substrate utilization kinetics and metabolic flexibility represent critical components of cardiovascular conditioning and endurance performance; however, the impact of continuous variations in aerobic capacity on the onset of metabolic transition requires detailed investigation.

Participants undergo anthropometric testing followed by a maximal graded exercise test on a motor-driven treadmill following the standard Bruce protocol. Breath-by-breath expired gas analysis using indirect calorimetry continuously monitors oxygen uptake (VO2), carbon dioxide production (VCO2), and minute ventilation (VE) throughout the test. Respiratory exchange ratio (RER) values are calculated continuously. The substrate crossover point is operationally defined as the exercise intensity corresponding to an RER threshold of 0.85, representing the metabolic transition where carbohydrate oxidation becomes the predominant contributor to total energy expenditure over lipid oxidation.

Key outcome measures extracted at this threshold include:

Time to reach the crossover point (minutes)

Absolute oxygen uptake at crossover (liters per minute [L/min])

Relative oxygen uptake at crossover (milliliters per kilogram per minute [mL/kg/min])

Percentage of maximal oxygen uptake at crossover (%VO2max)

Heart rate at crossover (beats per minute [bpm])

Statistical associations between maximal aerobic capacity (VO2max) and the primary outcome measures at the crossover point are analyzed using linear correlation and regression models to determine how cardiorespiratory fitness alters substrate switching kinetics under progressive physical strain.

Type d'étude

Interventionnel

Inscription (Réel)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Tepebaşi
      • Eskişehir, Tepebaşi, Turquie (Türkiye), 26100
        • Eskişehir Technical University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Healthy male or female physical education students aged 18 to 30 years
  • Regularly physically active (participating in structured physical activity at least 3 days per week)
  • Medically cleared and capable of performing maximal graded treadmill exercise testing to voluntary exhaustion
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • History of cardiovascular, pulmonary, metabolic, renal, or neuromuscular disorders
  • Acute musculoskeletal injury or orthopedic condition that impairs treadmill running or maximal exertion
  • Current use of prescription medications, stimulants, or dietary supplements known to alter metabolic rate, heart rate, or substrate oxidation
  • Use of tobacco, nicotine products, or alcohol within 24 hours prior to testing
  • Consumption of caffeine or vigorous physical exercise within 24 hours prior to the exercise trial

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Exercise Testing Group
: Healthy young adult participants who undergo a single maximal incremental treadmill exercise test using the Bruce Protocol to assess cardiorespiratory fitness (VO2max) and substrate crossover kinetics.
Participants perform a maximal treadmill exercise test following the standardized Bruce Protocol. The test begins with a warm-up, followed by progressive 3-minute stages with continuous increases in speed and incline until voluntary exhaustion. Indirect calorimetry is used continuously via breath-by-breath gas analysis to measure VO2VCO2, and RER for substrate crossover determination.
Autres noms:
  • Bruce Treadmill Protocol
  • Maximal Incremental Exercise Test
  • Graded Exercise Testing (GXT)
  • Maximal Treadmill Exercise Test

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Time to reach the substrate crossover point
Délai: Time Frame: Baseline (single test session, Day 1)

Measure Description: Elapsed time (in minutes) from the start of the incremental treadmill test (Bruce protocol) to the point where the respiratory exchange ratio (RER) reaches 0.85, indicating the metabolic crossover where carbohydrate oxidation becomes the predominant fuel source.

Time Frame: Baseline (single exercise test session, Day 1) Unit of Measure: Minutes

Time Frame: Baseline (single test session, Day 1)
Relative oxygen uptake at the crossover point
Délai: Measure Description: Measured continuously during the incremental exercise test using indirect calorimetry, recorded specifically at the point where the respiratory exchange ratio (RER) reaches 0.85. Time Frame: Baseline

Measure Title: Relative oxygen uptake at the substrate crossover point Measure Description: Oxygen uptake (VO2) normalized to body weight (mL/kg/min) recorded at the moment the substrate crossover point (respiratory exchange ratio [RER] = 0.85) is reached during the maximal incremental treadmill test (Bruce protocol).

Time Frame: Baseline

Measure Description: Measured continuously during the incremental exercise test using indirect calorimetry, recorded specifically at the point where the respiratory exchange ratio (RER) reaches 0.85. Time Frame: Baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of VO2max at the crossover point
Délai: Measure Description: Relative oxygen uptake (VO2) at the substrate crossover point (respiratory exchange ratio [RER] = 0.85) expressed as a % of the participant's maximal oxygen uptake (VO2max), calculated upon completion of the Bruce protocol

Measure Title: Percentage of maximal oxygen uptake at the substrate crossover point

Measure Description: Relative oxygen uptake (VO2) at the substrate crossover point (respiratory exchange ratio [RER] = 0.85) expressed as a percentage (%) of the participant's maximal oxygen uptake (VO2max) during the Bruce protocol treadmill test.

Time Frame: Baseline

Measure Description: Relative oxygen uptake (VO2) at the substrate crossover point (respiratory exchange ratio [RER] = 0.85) expressed as a % of the participant's maximal oxygen uptake (VO2max), calculated upon completion of the Bruce protocol
Heart rate at the crossover point
Délai: Measure Description: Heart rate (HR) in beats per minute (bpm) measured continuously during the incremental treadmill test (Bruce protocol), recorded at the substrate crossover threshold (respiratory exchange ratio [RER] = 0.85). Time Frame: Baseline

Measure Title: Heart rate at the substrate crossover point Measure Description: Heart rate (HR) recorded in beats per minute (bpm) using a telemetric heart rate monitor at the point where the substrate crossover threshold (respiratory exchange ratio [RER] = 0.85) is achieved during the maximal incremental treadmill test (Bruce protocol).

Time Frame: Baseline

Measure Description: Heart rate (HR) in beats per minute (bpm) measured continuously during the incremental treadmill test (Bruce protocol), recorded at the substrate crossover threshold (respiratory exchange ratio [RER] = 0.85). Time Frame: Baseline
Maximal oxygen consumption (VO2max)
Délai: Measure Description: Relative maximal oxygen uptake (VO2max in mL/kg/min) assessed at maximal exertion at the end of the Bruce protocol treadmill test to voluntary exhaustion via indirect calorimetry. Time Frame: Baseline

Measure Description:

The highest rate of relative oxygen uptake (VO2 in mL/kg/min) attained during the maximal graded exercise test (Bruce protocol) to voluntary exhaustion via indirect calorimetry.

Time Frame: Baseline

Measure Description: Relative maximal oxygen uptake (VO2max in mL/kg/min) assessed at maximal exertion at the end of the Bruce protocol treadmill test to voluntary exhaustion via indirect calorimetry. Time Frame: Baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: celil kaçoğlu, Ph.D., Eskişehir Teknik Üniversitesi

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mai 2026

Achèvement primaire (Réel)

30 juin 2026

Achèvement de l'étude (Réel)

15 juillet 2026

Dates d'inscription aux études

Première soumission

25 août 2026

Première soumission répondant aux critères de contrôle qualité

28 août 2026

Première publication (Réel)

2 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be publicly shared due to privacy and ethical constraints aimed at protecting participant confidentiality. However, de-identified aggregated data or specific data sets may be made available from the corresponding author upon reasonable academic request.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner